Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 5,277 matching trials from the live ClinicalTrials.gov search.

Filters: Gainesville, Florida Clear all

Conditions: Alzheimer Disease
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 33
States / cities: Tucson, Arizona • Irvine, California • Sacramento, California + 29 more

Conditions: Hemophilia A
Interventions: efanesoctocog alfa (BIVV001); Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Not listed
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • Gainesville, Florida + 12 more

Conditions: Acute Coronary Syndrome
Interventions: Milvexian, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14,194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 162
States / cities: Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more

Conditions: Chondrosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Rhabdomyosarcoma, Adult Malignant Meningioma, Adult Brain Malignant Hemangiopericytoma
Interventions: ifosfamide; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 65
States / cities: Scottsdale, Arizona • Duarte, California • Palo Alto, California + 46 more

Conditions: Pompe Disease (Late-onset)
Interventions: AT2221, ATB200; Drug · Biological
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Little Rock, Arkansas • Irvine, California • Gainesville, Florida + 14 more

Conditions: Aortic Aneurysm
Interventions: Endovascular Repair, Standard Open Repair; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 42
States / cities: Birmingham, Alabama • Tucson, Arizona • No. Little Rock, Arkansas + 39 more

Conditions: Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Carboplatin, Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Laboratory Biomarker Analysis, Paclitaxel, Pegfilgrastim, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 631
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 408 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 485
States / cities: Fairbanks, Alaska • Tucson, Arizona • Anaheim, California + 318 more

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 106
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more

Conditions: Psoriatic Arthritis
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Cystic Fibrosis
Interventions: azithromycin, placebo (for azithromycin), inhaled tobramycin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 12 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 39
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 33 more

Conditions: Lung Carcinoma
Interventions: Varenicline, Placebo, Tobacco Cessation Counseling; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 374
States / cities: Fairbanks, Alaska • Kingman, Arizona • Jonesboro, Arkansas + 236 more

Conditions: Chronic Traumatic Encephalopathy (CTE), Alzheimer Disease, Alzheimer Disease and Related Dementias (ADRD), Brain Injuries, Traumatic
Interventions: Not listed
Lead sponsor: Boston University; Other
Eligibility: 50 Years and older · Male only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 2 more

Conditions: Arthritis, Osteoarthritis, Osteoarthritis, Hip
Interventions: tanezumab, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 99
States / cities: Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Autologous Umbilical Cord Blood Transfusion, Cord blood; Procedure · Biological
Lead sponsor: University of Florida; Other
Eligibility: 1 Year and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Florbetapir F 18 PET Scan; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 77
States / cities: Anaheim, California • Imperial, California • Irvine, California + 59 more

Conditions: Percutaneous Coronary Intervention
Interventions: FFRangio, FFR or NHPR; Device
Lead sponsor: CathWorks Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,924 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 34 more

Conditions: Crohn's Disease
Interventions: natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 35
States / cities: Scottsdale, Arizona • Oceanside, California • San Francisco, California + 31 more

Conditions: Pancreas Tumor, Pancreatitis
Interventions: No Drains, Drains; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 12
States / cities: Gainesville, Florida • Tampa, Florida • Indianapolis, Indiana + 8 more

Conditions: Osteoporosis
Interventions: Bazedoxifene Acetate, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 7,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 205
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 141 more

Conditions: MDS
Interventions: Allogeneic Hematopoietic Cell Transplant, Hypomethylating Therapy / Best Supportive Care; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years to 75 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 37
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 28 more

Conditions: Low Back Pain
Interventions: Standard physical therapy, Graded exercise, Graded exposure; Behavioral · Other
Lead sponsor: University of Florida; Other
Eligibility: 15 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Endometriosis
Interventions: Placebo, OBE2109; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 71
States / cities: Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more

Conditions: Non-small Cell Lung Cancer
Interventions: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more

Search by objective public record fields.

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Psoriatic Arthritis Study of Izokibep

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

The DIAGNOSE CTE Research Project-II

Tanezumab in Osteoarthritis Of The Hip

Umbilical Cord Blood Infusion to Treat Type 1 Diabetes

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Pancreas Resection With and Without Drains

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

Effectiveness of Adding Behavioral Therapy to Physical Therapy to Treat Low Back Pain

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer